I mapped the money around Vivek Ramaswamy. Axovant implodes after failed Alzheimer’s trials. Insiders cash out. Investors get wiped. Two years later, a new biotech emerges in the same family orbit. Over $1.2B raised. No drugs to market. This is a pattern. Full timeline ⬇️